Author:
Tardos Jonathan,Aamir Nawal,Desai Dhaval,Chajkowski Amanda,H. Patel Amit
Abstract
The cornerstone for the modern treatment of paroxysmal atrial fibrillation (AF) is pulmonary vein isolation, also called an AF ablation. Various ablation technologies exist to accomplish this goal with specific advantages. This chapter will focus on the unique attributes of cryoablation for pulmonary vein isolation. Specifically, we will summarize the trial data and outcomes of cryoablation in patients with paroxysmal and persistent AF from the initial FDA approval studies to novel uses beyond the pulmonary veins. Readers will have an appreciation of the unique characteristics differentiating cryoablation from radiofrequency (RF) catheter ablation and other techniques such as surgical MAZE. Clinical trial data show both noninferiority, and in some cases, superior outcomes of cryoablation to antiarrhythmic drug therapy and other ablation techniques.
Reference42 articles.
1. Marine JE. Catheter ablation therapy for supraventricular arrhythmias. Journal of the American Medical Association. 2007;298(23):2768-2778
2. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes. Circulation Research. 2017;120:1501-1517. DOI: 10.1161/CIRCRESAHA.117.309732
3. Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: A Randomized Clinical Trial. Circulation. 2019;140(22):1779
4. Lip GY, Beevers DG. ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation. BMJ. 1995;311:1361-1363
5. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. American Heart Association Council on epidemiology and prevention statistics committee and stroke statistics subcommittee. Heart disease and stroke Statistics-2019 update: A report from the American Heart Association. Circulation. 2019;139:e56-e528